Markers of Inflammation and Incident Breast Cancer Risk in the Women's Health Study
A partir des données de la cohorte "The Women's Health Study" incluant 27 071 participantes (âge moyen : 54,5 ans), cette étude évalue l'association entre 4 marqueurs d'une inflammation chronique et le risque de cancer du sein (1 497 cas)
Chronic inflammation may be a risk factor for breast cancer development and progression, yet which inflammatory biomarkers and pathways are relevant is unknown. The study included 27,071 Women's Health Study participants (mean, 54.5 years old) free of cancer and cardiovascular disease at enrollment (1992 to 1995) with baseline measures of four inflammatory biomarkers: high sensitivity C-reactive protein (hsCRP), fibrinogen, N-acetyl side-chains of acute phase proteins (GlycA), and soluble intercellular adhesion molecule-1 (sICAM-1). We used Cox proportional hazards regression models to evaluate baseline concentrations of biomarkers for associations with incident breast cancer, adjusting for baseline and time-varying factors including age, body mass index, and other risk factors. Self-reported invasive breast cancer was confirmed against medical records for 1497 incident cases (90% postmenopausal). We observed different patterns of risk depending on the inflammatory biomarker. There was a significant direct association between fibrinogen and breast cancer risk (Q5 vs. Q1 adjusted HR = 1.25, 95% CI = 1.03, 1.51; P trend = 0.01). By contrast, sICAM-1 was inversely associated (Q5 vs. Q1 adjusted HR = 0.79, 95% CI = 0.66, 0.94; P trend = 0.02). GlycA and hsCRP were not associated with breast cancer. The complex association of chronic inflammation and breast cancer may need to be considered in formulating anti-inflammatory cancer prevention or intervention strategies